top
Search terms
Results 1 - 10 of 17 - ordered by :
Pages: 1 2
Ehjcvp

Recently the 2016 version of the European Guidelines on Cardiovascular Disease Prevention has been published by 10 major organizations within the framework of the Sixth Joint Task Force of the ...

European Heart Journal - Cardiovascular Pharmacotherapy, Editorials, Joep Perk

Date : 01/01/2017 Item size : 118151 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

Mean blood glucose changes in the placebo group were 0.6mmol/L (±3.1, P0.0002), 0.2 mmol/L (±2.7, P0.04), and 0.1 mmol/L (±3.0, P0.01) in the moderate, modest, and mild weight loss groups, ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Sadaf Kamil, Nicholas Finer, William Philip T James, Ian D. Caterson, Charlotte Andersson, Christian Torp-Pedersen

Date : 27/09/2016
Ehjcvp

Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies Abstract Aims ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Jung-Sun Kim, Sungha Park, Ping Yan, Barrett W. Jeffers, César Cerezo

Date : 05/08/2016
Ehjcvp

Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies Abstract Aims ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Jung-Sun Kim, Sungha Park, Ping Yan, Barrett W. Jeffers, César Cerezo

Date : 05/08/2016
Ehjcvp

Optimal handling of the healthy In the preventive section, the HOPE-3 (Heart Outcomes Prevention Evaluation 3) trial stole the limelight, first and foremost by strengthening faith in statinsthis time ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Manan Pareek, Deepak L. Bhatt

Date : 01/07/2016 Item size : 164372 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

The Systolic Blood Pressure Intervention Trial (SPRINT) enrolled 9300 participants age 50 years and older without diabetes or previous stroke in 100 expert medical centres and clinical practices ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Sverre E. Kjeldsen, Giuseppe Mancia

Date : 01/04/2016 Item size : 128053 bytes
Ehjcvp

Introduction Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have been used in clinical practice for more than a century and are among the most widely used drugs worldwide for the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, ...

Date : 01/04/2016 Item size : 461588 bytes
Ehjcvp

Abstract Aims To determine whether risk factor changes over 6 years were associated with the incidence of atrial fibrillation (AF) among middle-aged men in the Malmö Preventive Project (MPP) ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Linda S.B. Johnson, Tord Juhlin, Gunnar Engström, Peter M. Nilsson

Date : 01/04/2016